Interview with Charlotte Berg

On Saturday the 17th of November, the Swedish newspaper SvD, had an interview with the CEO, Charlotte Berg.

IDL Biotech AB offentliggör prospekt för beslutad företrädesemission

Styrelsen i IDL Biotech AB (Publ) har upprättat ett prospekt med anledning av den förestående nyemissionen med företrädesrätt för IDL Biotechs aktieägare. Prospektet har idag godkänts och registrerats av Finansinspektionen.

Information from Extraordinary General Meeting

The Extraordinary meeting was held on 2018-10-26.

Redeye Life Science Day

IDL Biotech will attend Redeye Life Science Day on November 21, at Haymarket City Scandic Stockholm, Hötorget 13-15, Stockholm. Charlotte Berg, CEO, will have her presentation at 1 pm. The presentation is live on www.redeye.se/live/lsday-2018. You can follow the presentation through the computer or cellphone.

IDL strengthens the team with Regional Manager Asia Pacific

IDL has appointed Nick Thilveris as our new Regional Manager Asia Pacific

Notice of Extra Annual General Meeting

The Extra Annual General Meeting will be held 25th of October.

New Share Issue

The board of directors of IDL Biotech AB (publ) has resolved to make a new share issue of approximately SEK 39,4 million before issue costs.

IDL to strengthen global sales

IDL Biotech today announced that they are strengthening their global Sales and Marketing team. Martyn Eales has been named Senior Vice President of Global Sales and Marie Torstensson has been named Marketing Manager. Together they will lead the effort to increase international sales.

Patent approved in Europe

During 2015 the patent ”Method for detection of cytokeratin 8, 18 and/or 19 and/or soluble fragments thereof” was approved in Sweden. In September 2017 the patent was approved in China. The patent has now also been approved in Europe and is valid until 2034.

Per-Anders Abrahamsson New Scientific Advisor to IDL Biotech AB

Per-Anders Abrahamsson, MD, PhD, Professor in Urology, has been working as urologist for 40 years, out of which 20 years as Head of the Department of Urology, Skåne University Hospital (Malmö/Lund, Trelleborg and Landskrona), Adjunct Secretary General at the European Association of Urology (EAU) 2004-2007 responsible for Science, EAU Secretary General 2007 – 2015, Vice President Global Medical Affairs Uro-oncology, Ferring Pharmaceuticals A/S and Member of the Board at Camurus AB.

IDL Biotech support CancerRehabFonden.

One  in three people in Sweden will develop cancer in their life time. Rehabilitation can help cancer patients to recover, both mentally and physically.  CancerRehabFonden is an Swedish independent organization that provides cancer rehabilitation free of charge.

Positive results for TPS®

Results from a Czech Republic study.

Claes Henning New Scientific Advisor

IDL Biotech continues to strengthen its scientific knowledge by appointing an additional experienced scientific advisor.

Positive results for UBC® Rapid in an Austrian study

International Journal of Medical Sciences has published an Austrian study with UBC® Rapid performed at the Department of Urology, Medical University of Innsbruck. Urinary samples were analyzed by cytology, UBC® Rapid and NMP22 BladderChek® test.

UBC® Rapid is recommended to be added in the diagnostics of high grade bladder cancer tumours

Results from a published multicenter study

Hans Örström new Chariman of the Board

The annual general meeting, held 23rd of May 2017, approved the re-election of Jerker Swanstein, Max Pihlqvist, Hans Örström and Peter Brätuigam. During the statutory meeting held 24th of May 2017 Hans Örström was selected as new Chariman of the Board.

Positive results for UBC® Rapid in a Swedish multicenter study

The study published in Scandinavian Journal of Urology (https://www.ncbi.nlm.nih.gov/pubmed/28422550) was conducted at four Swedish hospitals; Uppsala University Hospital, Danderyds hospital, Enköping Hospital and Umeå University Hospital. Principal investigators was Assoc. Prof Amir Sherif, Umeå University.

Charlotte Berg new CEO

New interesting findings for the tumor marker UBC® Rapid

Result from a new German multicenter study

TUBEX® is getting wider recognition and awareness – Now on social Media.

TUBEX® is getting wider recognition and awareness – Now on social Media.

MonoTotal ELISA has been CE marked in accordance with the European IVD Directive

IDL Biotech tumor marker MonoTotal® ELISA has been registered by the Swedish Medical Product Agency for the use in the EU.

Positive results for UBC Rapid in Clinical study

Evaluation of bladder cancer with point-of-care (POC) tests depends on the detection of bladder cancer associated proteins in urine samples.